

## Special Issue

# Therapeutic Nanoparticles for Drug Delivery in Cancer

### Message from the Guest Editors

In the last decade, therapeutic nanoparticles have gained increasing interest in many fields of medicine. These vectors have been proven to offer novel diagnostic and therapeutic applications for drug delivery against cancer, due to their unique chemical–physical properties, such as size, surface characteristics and interaction with biomolecules. The high surface/volume ratio and surface bioreactivity make nanoparticles ideal multifunctional platform carriers for selective tumor targeting and treatment. Many authors have recently contributed to improve the active targeting of drug-loaded nanocarriers to boost anticancer activity, but the results are often limited to in vitro models. This Special Issue intends to focus on the versatility of nanoparticles by expanding the knowledge on how the peculiar biology and chemistry of cancer tissues can be used for their selective targeting and for engineering novel nanovectors.

---

### Guest Editors

Dr. Donato Colangelo

Department of Health Sciences, Università del Piemonte Orientale  
UPO, 28100 Novara, Italy

Dr. Stelvio Tonello

Department of Translational Medicine, Università del Piemonte  
Orientale UPO, 28100 Novara, Italy

---

### Deadline for manuscript submissions

closed (31 January 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/172491](https://mdpi.com/si/172491)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)